XT
RNAC icon

XTX Topco’s Cartesian Therapeutics RNAC Stock Holding History

XTX Topco’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
19,395
-10,660
-35% -$79K ﹤0.01% 3244
2026
Q1 		$185K Buy
30,055
+19,817
+194% +$141K ﹤0.01% 2872
2025
Q4 		$73.8K Sell
10,238
-16,021
-61% -$130K ﹤0.01% 2728
2025
Q3 		$0 Buy
+26,259
New +$295K ﹤0.01% 3160
2024
Q1 		– Sell
-1,195
Closed -$24.7K – 2244
2023
Q4 		$24.7K Sell
1,195
-1,638
-58% -$48.9K 0.01% 1339
2023
Q3 		$90.1K Sell
2,833
-2,108
-43% -$70.4K 0.02% 1197
2023
Q2 		$166K Buy
+4,941
New +$177K 0.03% 1073
2023
Q1 		– Sell
-6,226
Closed -$211K – 1609
2022
Q4 		$211K Sell
6,226
-165
-3% -$7.02K 0.04% 808
2022
Q3 		$314K Buy
6,391
+3,910
+158% +$215K 0.08% 471
2022
Q2 		$97K Sell
2,481
-1,573
-39% -$46.6K 0.04% 655
2022
Q1 		$150K Buy
4,054
+2,934
+262% +$184K 0.07% 459
2021
Q4 		$110K Buy
+1,120
New +$120K 0.06% 455
2021
Q3 		– Sell
-1,063
Closed -$133K – 1011
2021
Q2 		$133K Buy
+1,063
New +$127K 0.04% 626

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco's RNAC Position: Q2 2026 in Review

XTX Topco reduced its Cartesian Therapeutics (RNAC) stake by 35% in Q2 2026, selling an estimated $79K and leaving 19,395 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #3244.

XTX Topco first reported a position in RNAC in Q2 2021 and has held it in 13 quarters since. The position peaked at $314K in Q3 2022. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • XTX Topco held 19,395 shares of Cartesian Therapeutics worth $202K as of Q2 2026.
  • XTX Topco sold 10,660 Cartesian Therapeutics shares in Q2 2026, an estimated $79K.
  • Cartesian Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3244 holding.
  • XTX Topco first reported a position in Cartesian Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • XTX Topco's Cartesian Therapeutics position peaked at $314K in Q3 2022.
  • 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.